## THE U.S. ZIKA PREGNANCY REGISTRY

**CALIFORNIA DATA SUBMISSION PROCESS** 

## **Infant Follow-up Form**

The California Department of Public Health (CDPH) is participating in the U.S. Zika Pregnancy Registry and is the point of contact for California data submission to the Centers for Disease Control and Prevention (CDC).

If you require this document in an alternate format, please contact ZikaOutcomes@cdph.ca.gov.

### Who Is Eligible for the Registry?

- Pregnant women in the United States with laboratory evidence of Zika virus infection (positive or equivocal test results, regardless of whether they have symptoms) and periconceptionally, prenatally, or perinatally exposed infants born to these women.
- Infants with laboratory evidence of congenital Zika virus infection (positive or equivocal test results, regardless of whether they have symptoms) and their mothers.

To participate, follow the directions below:

#### **Healthcare Provider Instructions Local Health Department Instructions** Healthcare providers should contact their Local Local Health Departments may choose to follow Health Department (LHD) for questions about up with healthcare providers or ask CDPH staff to follow-up. LHDs should inform CDPH of the LHD data submission. Providers may be contacted by either the LHD or preference at: ZikaOutcomes@cdph.ca.gov. CDPH for Zika pregnancy and infant outcomes Various methods (e.g., medical record data collection. abstraction, telephone interview) can be used to Visit the US Zika Pregnancy Registry webpage for collect surveillance information for the Registry. more information on reporting Zika pregnancy LHDs contacting providers to complete the and infant outcomes to CDPH. Registry forms directly should insert the LHD contact information below for provider submission. LHDs should ensure completion of the attached form and then submit to CDPH by e-mail or fax as instructed below. FORM PROCESSING INSTRUCTIONS Send Registry forms to: ☐ My Local Health Department at the address ☐ California Department of Public Health below: Fax: (510) 620-3152 Phone: (510) 620-3151 Email: ZikaOutcomes@cdph.ca.gov Phone: (Please send a message for instructions before submission).

#### Security note:

- -Call prior to faxing forms to CDPH or Local Health Department.
- -Please **DO NOT** scan and email documents before receiving instructions.

HIPAA Privacy Rule permits providers to disclose PHI without authorization to public health authorities for the purposes of preventing or controlling disease.

The CDPH California Birth Defects Monitoring Program (CBDMP) is authorized to conduct studies to investigate the causes of birth defects (H&S section 103840).



REDCar	o ID		

Infant	ID			



# U.S. Zika Pregnancy and Infant Registry Infant Follow-Up Form

These data are considered confidential and will be stored in a secure database at the Centers for Disease Control and Prevention

Please return completed form via secure fax to 510-620-3152 or encrypted email to <a href="mailto:ZikaOutcomes@cdph.ca.gov">ZikaOutcomes@cdph.ca.gov</a>

1. General, Growth a	nd Trave	el Informa	tion					
Infant follow up: ☐ 2 months ☐ 6 months ☐ 12 months ☐ 18 months ☐ 24 months ☐months								
IFU.1. State/Territory rep	IFU.1. State/Territory reporting:							
IFU.2. Infant's State/Territory ID	IFU.3. N State/Te	lother's erritory ID						
Infant death								
IFU.6. Infant Death:	_							
IFU.7. If yes, caus IFU.8. If yes, date							Unknown/No	t stated
Growth								
lbsoz								
IFU.10. Date of measure	IFU.10. Date of measurement:     IFU.12. Date of measurement:     IFU.14. Date of measurement:				ment: —			
Optional Section  Postnatal travel Only complete if infant received PRNT testing								
<b>IFU.15.</b> Postnatal travel to an area with active Zika virus transmission <i>mark one</i> ☐ Yes ☐ No ☐ Unknown/Not stated								
IFU.16. Location of expo	sure (1)		IFU.17.	Start Date			IFU.18. End Date	
IFU.19. Location of expo	sure (2)		IFU.20. S	Start Date			IFU.21. End Date	
IFU.22. Location of exposure (3)  IFU.23. Start Date  IFU.24. End Date								

REDCap	ID.	

Infant I	ID			
IIIIaiii	טו			

2. Neurologic Sequelae	
Physical exam or neurological evaluation  IFU.25. Physical exam or neurological evaluatio  ☐ Yes - If "Yes", complete the section below  ☐ No - If "No", skip to "Developmental Asses  ☐ Unknown/Not Stated - If "Unknown/Not stated"	
IFU.26. Date of exam or evaluation:	
<b>IFU.27.</b> Findings from physical exam or neurolo	gical evaluation: check all that apply
☐ Normal	
Neurologic sequelae  □ Seizures  Body tone abnormalities  □ Hypertonia/spasticity □ Hyperreflexia □ Hypotonia  Movement abnormalities □ Dyskinesia or dystonia □ Tremors □ Swallowing/feeding difficulties  Signs of possible visual impairment □ Failure to fix and follow □ Nystagmus □ Esotropia/Strabismus □ Irritability  IEU 28 Describe findings identified in IEU 27:	Contractures with brain anomalies  ☐ Arthrogryposis (congenital joint contractures) ☐ Congenital talipes equinovarus (clubfoot) ☐ Congenital hip dislocation/developmental
<b>IFU.28.</b> Describe findings identified in <b>IFU.27.</b> :	

REDCap ID	)

Infant ID\_\_\_\_\_

3. Developmental Assessment
IFU.29. Overall interpretation of development: mark one  ☐ Normal - If "Normal", complete the section below  ☐ Abnormal - If "Abnormal", complete the section below  ☐ Unknown/Not stated - If "Unknown/Not stated", skip to "Neurological Imaging Studies" (page 4)
IFU.30. Date of exam:
<b>IFU.31.</b> Areas of developmental delay: <i>check all that apply</i> □ No delays □ Gross motor □ Fine motor □ Cognitive- linguistic and communication □ Socio-Emotional
IFU.32. Describe all abnormal findings:
<b>IFU.33.</b> Standardized developmental assessment or evaluation performed: mark one
☐ Yes If "Yes", IFU.34. Type of assessment:
□ No
☐ Unknown/Not stated

4. Neurological Imaging Studies – findings of conge	enital anomalies of the brain/spinal cord
IFU.35. Neurological imaging studies performed: mark on  ☐ Yes - If "Yes", complete the section below ☐ No - If "No", skip to "Audiological Screening and Eve	
<b>IFU.36.</b> Neurological imaging type: <i>mark one</i> ☐ Cranial	
Other:	uitiasounu 🗀 Wiki 🗀 Ci
IFU.37. Date of imaging:	
IFU.38. Findings from neurological imaging study: check a	II that apply
<ul> <li>□ Normal</li> <li>□ Microcephaly</li> <li>□ Intracranial calcifications</li> <li>□ Cerebral/cortical atrophy</li> <li>□ Abnormal cortical formation</li> <li>(polymicrogyria, lissencephaly, pachygyria, schizencephaly, gray matter heterotopia, agyria, microgyria)</li> <li>□ Corpus callosum abnormalities</li> <li>□ Cerebellar abnormalities</li> </ul> IFU.39. Describe all findings identified in IFU.38.:	□ Porencephaly □ Hydranencephaly □ Moderate or severe ventriculomegaly/hydrocephaly □ Encephalocele □ Holoprosencephaly/ arhinencephaly □ Other abnormalities - Please describe:
	ultrasound
Other:	
IFU.41. Date of imaging:	II that apply
IFU.42. Findings from neurological imaging study: check a  □ Normal □ Microcephaly □ Intracranial calcifications □ Cerebral/cortical atrophy □ Abnormal cortical formation (polymicrogyria, lissencephaly, pachygyria, schizencephaly, gray matter heterotopia, agyria, microgyria) □ Corpus callosum abnormalities □ Cerebellar abnormalities	☐ Porencephaly ☐ Hydranencephaly ☐ Moderate or severe ventriculomegaly/hydrocephaly ☐ Encephalocele ☐ Holoprosencephaly/ arhinencephaly ☐ Other abnormalities - Please describe:
IFU.43. Describe all findings identified in IFU.42.:	

REDCap ID
NEDC.4D 1D

Infant I	D

5. Audiological Screening and Evaluation
Hearing screening or re-screening, excluding birth hospitalization hearing screening  IFU.44. Hearing screening performed: mark one  ☐ Yes - If "Yes", complete the section below  ☐ No - If "No", skip to "Audiological evaluation" (page 5)  ☐ Unknown/Not stated - If "Unknown/Not Stated", skip to "Audiological Evaluation" (page 5)
IFU.45. Date of screening:
IFU.46. Hearing screening results: mark one  □ Pass □ Fail or referred □ Unknown/Not stated □ Abnormal, unilateral □ Abnormal, bilateral □ Abnormal, laterality unknown/not stated □ IFU.48. Provide any additional comments from hearing screening:
Audiological evaluation  IFU.49. Audiological evaluation performed: mark one  ☐ Yes - If "Yes", complete the section below ☐ No - If "No", skip to "Congenital Anomalies of the Eye" (page 6)  ☐ Unknown/Not stated - If "Unknown/Not Stated", skip to "Congenital Anomalies of the Eye" (page 6)
IFU.50. Date of evaluation:
IFU.51. Overall interpretation of audiological evaluation: mark one ☐ Unknown/Not stated ☐ Normal ☐ Abnormal, unilateral ☐ Abnormal, bilateral ☐ Abnormal, laterality not stated  IFU.52. If overall interpretation is abnormal, indicate type(s) of hearing loss and severity of hearing loss: mark all that apply Type of hearing loss ─ mark all that apply ☐ Conductive hearing loss ☐ Sensorineural hearing loss ☐ Mixed hearing loss ☐ Auditory neuropathy spectrum disorder ☐ Hearing loss, type unknown/not stated Severity of hearing loss ─ mark all that apply ☐ Mild ☐ Moderate ☐ Moderately severe ☐ Severe ☐ Profound ☐ Severity unknown/not stated  IFU.53. Provide any additional comments from audiological evaluation:
iro.33. Frovide any additional comments from additionglear evaluation.

REDCa	p ID	1		

Infant ID\_\_\_\_\_

6. Congenital Anomalies of the Eye				
IFU.54. Retinal exam: mark one				
☐ Yes - If "Yes", complete the section below				
$\square$ No - If "No", skip to "Additional Studies and Evaluation" (page 7)				
☐ Unknown/Not stated - If "Unknown/Not stated", skip to "Additional Studies and Evaluation" (page 7)				
IFU.55. Date of exam:				
<b>IFU.56.</b> Overall eye findings: <i>mark one</i> □ Unknown/Not stated				
$\square$ Normal $\square$ Abnormal, unilateral $\square$ Abnormal, bilateral $\square$ Abnormal, laterality not stated				
<b>IFU.57</b> . Visual acuity/impairment: <i>mark one</i> ☐ Unknown/Not stated				
$\square$ Normal $\square$ Abnormal, unilateral $\square$ Abnormal, bilateral $\square$ Abnormal, laterality not stated				
IFU.58. If eye findings are abnormal, indicate all abnormal findings: check all that apply  ☐ Microphthalmia/anophthalmia ☐ Cataract ☐ Intraocular calcifications ☐ Coloboma ☐ Coloboma ☐ Coloboma of the iris ☐ Coloboma of the retina or optic nerve ☐ Chorioretinal anomalies involving the macula (e.g., chorioretinal atrophy and scarring, macular pallor, gross pigmentary mottling) ☐ Optic nerve atrophy, pallor ☐ Other optic nerve abnormalities - Please describe:				
IFU.59. Describe all findings identified in IFU.56.— IFU.58.:				

7. Additional Studies and Evaluation						
IFU.60. Other studies performed: mark one  ☐ Yes - If "Yes", complete the section below ☐ No - If "No", skip to "Health Department Information" (page 7)						
☐ Unknown/Not stated - If "Unknown/Not stated", skip to "Health Department Information" (page 7)						
<b>IFU.61.</b> Study type: <i>mark one</i> ☐ Electroencephalogram (EEG) ☐ Swallowing evaluation ☐ Hip ultrasound ☐ Other:						
IFU.62. Date of study:						
IFU.63. Overall interpretation: mark one ☐ Normal ☐ Abnormal ☐ Unknown/Not stated IFU.64. Describe abnormal findings:						
<b>IFU.65.</b> Study type: <i>mark one</i> ☐ Electroencephalogram (EEG) ☐ Swallowing evaluation ☐ Hip ultrasound ☐ Other:						
IFU.66. Date of study:						
<b>IFU.67.</b> Overall interpretation: $mark\ one\ \square$ Normal $\ \square$ Abnormal $\ \square$ Unknown/Not stated						
IFU.68. Describe abnormal findings:						
8. Health Department Information						
Name of person completing form: Email:						
Date of form completion:						
Internal use only						
Date entered Data Entry Notes:  Data Entry POC Initials:						
Public reporting burden of this collection of information is estimated to average 15 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSI						